A new study confirms the long-term benefits of hydroxyurea for children with sickle cell disease. The oral drug significantly reduced hospital visits and stays. Despite its origins as a chemotherapy drug, the study highlights its safety and effectiveness in improving the health outcomes of affected children, particularly with consistent use.
